Accelerating molecular discovery using an in silico design platform

Parc Científic de Barcelona - Schrödinger

Parc Científic de Barcelona  -    Sala Dolors Aleu - Edifici Clúster II

Take a break from your other obligations and let’s talk! Schrödinger together with Parc Científic de Barcelona invite you to join us on Tuesday, July 8th at PCB's Sala Dolors Aleu for an extended version of Schrödinger's Lunch and Learn series where we will introduce the diverse capabilities of Schrödinger’s molecular design platform. Schrödinger scientists will present how modern physics-based simulation methods as well as machine learning can help to create better molecules faster and answer your questions around computer-driven molecular design.Event programme09:30-09:35 Welcome and opening, Grisha Domakowski, Parc Cientific de Barcelona Commercialization &amp; Communication Director.09:35 - 11:30Accelerating biologics design through computational modelling and collaborative enterprise informaticsDan Cannon, Principal Scientist II, Applications SciencesThis Schrödinger workshop will explore how to use physics-based computational methods (BioLuminate, FEP+) and collaborative enterprise informatics (LiveDesign) to accelerate biologics design. We will present case studies on large scale mutagenesis for affinity, analysing and correcting developability issues, variant selection based on cross-reactivity, multi-parameter ideation and more. Whether you're new to computational tools or looking for a deeper dive into advanced methods, this session is designed to provide valuable insights for all experience levels. 11.30-12:00 Coffee break 12:00 - 14:00Accelerating small-molecule drug discovery combining physics-based methods, machine learning techniques and digital chemistryDavid Rinaldo, Senior Principal Scientist, Applications ScienceDrug Design is a highly complex task literally consisting in finding a molecule with defined properties in the ocean of all possible molecules. In the past 10 years the field has experienced dramatic changes including an explosion in the size of commercial chemical libraries, a significant increase in available computing power (GPU, cloud computing), and significant advances in machine learning techniques (the so-called AI revolution). In this workshop we will see how Schrödinger has been leveraging those technological revolutions to accelerate the small-molecule drug discovery process.In the first part of this workshop, we will present a few physics-based methods Schrödinger has been recently developing and then we will see how those techniques can efficiently be combined to efficiently and collaboratively find new drug candidates.14:00 -15:00 LunchRegister today to secure your seat!The workshop is free to attend but pre-registration is required as seats are limited. Previous-experience with the Schrödinger suite is not required.Speakers BIODan CannonPrincipal Scientist II, Applications Science. SchrödingerDan Cannon is a Principal Applications Scientist at Schrödinger and the EU lead for biologics services. Prior to joining Schrödinger, Dan received his Ph.D. from the University of Strathclyde in Glasgow, UK, under the supervision of Prof. Tell Tuttle. In 2016, he began working at MedImmune in Cambridge, UK, using computational approaches for therapeutic protein design before joining Schrödinger in August of 2018 In his role as Applications Scientist he uses his expertise in biologics towards developing novel computational protein design and analysis workflows and enables customers to leverage protein structures towards rational design.David RinaldoSenior Principal Scientist, Applications Science. SchrödingerIn 2003, David Rinaldo received his PhD from the Université Joseph Fourier working on metalloproteins under the supervision of Martin J. Field at the Institut de Biologie Structurale in Grenoble. For his post-doc, he then moved to Columbia University where he was studying metalloenzymes mechanisms using QM and QM/MM methods in Richard Friesner’s laboratory. Following his post-doc, he joined Schrodinger in 2007 as Applications Scientist where he has been supporting customers in Europe. He is now Senior Principal Scientist at Schrodinger and is advising customers on using the Schrodinger’s small molecule drug discovery Suite.